Saturday 17 October 2026 Export STAA’s income statement to Excel — free account

STAAR Surgical Company

STAA Healthcare Medical Instruments & Supplies

In the quarter to June 2026, revenue grew 111.0%, EPS grew 147.1% and free cash flow grew 166.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

21.27 0.99 −4.45%

Follow STAA

Alert me

Market cap: $1.1B
P/E: 304×
Fwd P/E: 103×
Dividend yield: —
F-score: 2/9
Altman Z: 6.44
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 62.75

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	2	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 39.75%

Capital & Financial Ratios $m

Market Cap 1,120.00

Revenue 339.59

Net Income 3.84

Free Cash Flow (6.75)

Net Debt (181.49)

Current Ratio 4.66

Debt/Equity 0.00

P/E ratio 303.86

Fwd P/E 103.00

P/S ratio 3.15

P/B ratio 2.93

Past 5Y EPS Growth —

This Y EPS Growth 129.06%

Next Y EPS Growth 88.23%

Next Y revenue growth 39.62%

Next 5Y EPS Growth 43.03%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 65.99%

10-year low 10-year high

P/S against its own 10 years 4.46%

10-year low 10-year high

P/B against its own 10 years 7.74%

10-year low 10-year high

EV/Sales against its own 10 years 4.79%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	221	230	188	181
Receivables	95	78	50	98
Inventory	35	43	55	47
Other	—	—	—	—
	365	368	312	342

	2023	2024	2025	Q'26
Payables	14	17	12	13
ST’ Debt	—	—	—	—
Other	47	50	51	54
	65	70	69	73

Compound Annual Growth %

	10y	5y	3y
Sales	12.00%	7.93%	(5.57%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	24.38%	11.78%	0.79%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	94	94	—	—	—
’25	43	44	95	58	239
’24	77	99	89	49	314
’23	74	92	80	76	322
’22	63	81	76	64	284
’21	51	62	58	59	230
’20	35	35	47	46	163

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	20	—	—	—
’25	(6)	(27)	3	(4)	(34)
’24	22	(10)	4	1	16
’23	(5)	(6)	(6)	32	15
’22	(5)	13	24	3	36
’21	7	6	22	8	44
’20	(8)	0	10	20	21

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	19	—	—	—
’25	(7)	(29)	2	(6)	(40)
’24	16	(17)	(2)	(5)	(8)
’23	(8)	(9)	(15)	29	(4)
’22	(7)	8	18	(1)	18
’21	5	3	19	4	30
’20	(10)	(2)	8	17	13

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.10	0.16	—	—	—
’25	(1.10)	(0.34)	0.18	(0.37)	(1.62)
’24	(0.07)	0.15	0.20	(0.69)	(0.41)
’23	0.05	0.12	0.10	0.16	0.43
’22	0.19	0.26	0.21	0.12	0.78
’21	0.10	0.17	0.12	0.16	0.50
’20	0.00	(0.03)	0.08	0.07	0.12

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.98	8.95	13.60	21.70	23.20	77.74	46.36	30.29	23.55	13.50	Analyst estimates 2026–2028 Powerpack
	High	11.50	17.60	54.00	41.65	85.63	163.08	112.27	81.81	52.68	30.81
People
People	Employees	336	353	475	550	575	806	964	1,115	1,211	957
	Revenue/emp, $m	0.25	0.26	0.26	0.27	0.28	0.29	0.30	0.29	0.26	0.25
Income, $m
Income, $m	Revenue	82	91	124	150	163	230	284	322	314	239
	Gross margin, %	70.81	70.94	73.83	74.54	72.41	77.51	78.55	78.36	76.32	76.19
	EBT	(12)	(2)	7	13	8	31	46	34	(9)	(82)
	EBT margin, %	(15.10)	(2.53)	5.36	8.67	5.06	13.58	16.02	10.45	(2.88)	(34.36)
	Net income	(12)	(2)	5	14	6	28	40	21	(20)	(80)
	Depreciation	3	3	2	4	3	4	3	3	6	9
Per share, $
Per share, $	Revenue	2.04	2.21	2.91	3.38	3.58	4.88	5.93	6.64	6.39	4.83
	Earnings	(0.30)	(0.05)	0.12	0.32	0.13	0.52	0.81	0.44	(0.41)	(1.62)
	Cash flow	0.03	0.07	0.30	0.58	0.46	0.93	0.74	0.30	0.32	(0.69)
	Capex	(0.08)	(0.03)	(0.05)	(0.23)	(0.18)	(0.29)	(0.38)	(0.37)	(0.48)	(0.12)
	Free cash flow	(0.05)	0.04	0.25	0.35	0.28	0.64	0.37	(0.07)	(0.16)	(0.81)
	Book value	0.94	1.05	3.11	3.59	4.32	5.48	7.00	7.95	8.09	6.94
	Shares, m	40	41	43	44	46	47	48	49	49	50
Valuation, ×
Valuation, ×	P/E	0.00	0.00	306.53	113.45	677.09	155.54	64.06	66.07	0.00	0.00
	P/S	5.23	7.20	10.96	10.42	22.10	18.70	8.65	4.47	3.80	4.78
	P/B	11.38	15.18	10.26	9.79	18.32	16.67	7.32	3.74	3.00	3.33
	EV/Sales	5.08	7.00	10.13	9.62	21.17	17.84	7.90	3.79	3.07	4.13
	EV/FCF	(194.28)	350.84	119.32	92.54	277.63	135.97	128.28	(332.31)	(124.20)	(24.65)
Cash, $m
Cash, $m	Operating cash flow	1	3	13	26	21	44	36	15	16	(34)
	Capex	(3)	(1)	(2)	(10)	(8)	(14)	(18)	(18)	(23)	(6)
	Free cash flow	(2)	2	11	16	13	30	18	(4)	(8)	(40)
Balance, $m
Balance, $m	Working capital	28	35	124	140	175	223	260	300	298	243
	Total debt	1	1	0	0	0	0	0	0	—	—
	Net debt	(13)	(18)	(103)	(120)	(152)	(199)	(211)	(221)	(230)	(188)
	Shareholders’ equity	38	43	132	160	197	259	336	386	397	344
Returns, %
Returns, %	ROA	(18.89)	(3.21)	4.22	7.50	2.54	9.12	10.38	4.70	(4.05)	(16.74)
	ROIC	(31.33)	(9.10)	14.21	18.39	9.44	35.18	21.96	10.63	(4.72)	(36.59)
	ROE	(31.61)	(5.29)	5.67	9.61	3.31	12.07	13.34	5.91	(5.16)	(21.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%	Compare
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%	Compare
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%	Compare
KMTS Kestra Medical Technologies, Ltd.	$1.7B	— (loss-making)	— (loss-making)	+59.88% (above 0%: growing)	n/m	−17.75% (below 0%: shrinking)	56.50%	(121.59%)	Compare
AZTA Azenta, Inc.	$1.6B	— (loss-making)	— (loss-making)	+12.04% (above 0%: growing)	n/m	−134.69% (below 0%: shrinking)	44.89%	(2.59%)	Compare
STAA STAAR Surgical Company	$1.1B	304×	103×	+111.04% (above 0%: growing)	n/m	+166.10% (above 0%: growing)	74.55%	10.80%
AVR Anteris Technologies Global Corp.	$619.8M	— (loss-making)	—	+63.27% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.91%	(3,072.05%)	Compare
ANGO AngioDynamics, Inc.	$487.0M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)	Compare
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
Median of peers	$1.7B	—	31.5×	+12.04%	—	−6.84%	59.37%	(2.59%)

All 55 Medical Instruments & Supplies stocks →

STAAR Surgical Company (STAA) key facts

STAAR Surgical Company (STAA) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, STAA traded at $21.27, a market capitalization of $1.1 billion.
Return on equity was −21.7% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 6.44 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.